Table 1.

On the left side of the table are the five dimensions of FAST with the available options which the clinician can choose between (e.g., “Phenotype” can be “relapse-remitting,” “secondary progressive,” etc.) and the different subdimensions [e.g., “Disease dynamics” is defined by information about the current Expanded Disability Status Scale (EDSS), activity, progression, and worsening].

Patient name: Age: 1.Phenotype –Relapse-remitting disease –Secondary progressive disease –Primary progressive disease –Clinically isolated syndrome –Radiologically isolated syndrome 2.Disease dynamics 2.1Current EDSS 2.2Activity (clinical/imaging) –Not active –Active –Highly active 2.3Progression (clinical) –Without progression –With progression 2.4Worsening (clinical) –Worsening –Stable 3.Diagnostic information 3.1Time of first symptoms 3.2Time of first diagnosis 3.3Revised McDonald criteria 3.4Cerebrospinal fluid (CSF) and other relevant laboratory findings 4.Disease-modifying therapy (DMT) 4.1Current DMT (xxxx–until now) –Annualized relapse rate or progression during this period –Other relevant aspects (e.g., anti-JC-virus antibody serum levels) 4.2Previous DMT 1 (xxxx–xxxx) –Annualized relapse rate or progression during this period –Other relevant aspects (e.g., anti-JC-virus antibody serum levels) 4.2Previous DMT 2 (xxxx–xxxx) 5.Related medical conditions

Patient name: X Age: 27 1.Phenotype: relapse-remitting disease 2.Disease dynamics 2.1Current EDSS: 3 2.2Activity: active [two relapses 2016–2017 (one optic neuritis and one transverse myelitis) as well as a new MRI lesion] 2.3Progression: without progression 2.4Worsening: worsening (2016–2017: EDSS increase from 2 to 3 due to growing vision loss of the left eye) 3.Diagnostic information 3.1Time of first symptoms: 01/2010 3.2Time of first diagnosis: 05/2012 3.3Revised McDonald criteria: –Clinical criteria for dissemination in time and space are met –MAGNIMS criteria are met 3.4CSF and other relevant laboratory findings: –05/2012: 17 leukocytes/μl, oligoclonal banding –06/2016: 14 leukocytes/μl, oligoclonal banding, JCV-PCR negative, aquaporin-4-antibodies negative in serum and CSF 4.DMT 4.1Current DMT (01/2016–until now): dimethyl fumarate –Annualized relapse rate: 2/year –Other relevant aspects: Lymphocyte count 01/2017: 1.69/nl Anti-JCV antibody serological index 01/2016: negative 01/2017: negative 4.2Previous DMT (05/2012–12/2016): glatiramer acetate –Annualized relapse rate: 2/year –Other relevant aspects: mild skin irritation reaction 5.Related medical conditions –Hashimoto’s thyroiditis –Patient is planning to have a child in the next 1 or 2 years.

An example for a fictional patient and how the five-dimensional approach for surveillance and therapy (FAST) can be applied in the clinical practice is shown on the right side of the table.